Analysis of rod/cone gap junctions from the reconstruction of mouse photoreceptor terminals
Abstract
This project was inspired by the paper from Behrens et al (2016) who used e2006 to reconstruct bipolar cells. We thank Christian Behrens, Timm Schubert, Philipp Berens and Thomas Euler (University of Tübingen) for generously sharing data on blue cone bipolar cells. We thank Moritz Helmstaedter (MPI, Frankfurt) for hosting the e2006 dataset. We thank Kiril Martemyanov (Scripps research Institute, Jupiter, Florida) for the generous gift of an mGluR6 antbody. We thank David Berson (Brown University), for advice, encouragement and an introduction to connectomics. We thank Jessica Riesterer at the Multiscale Microscopy Core, an OHSU University Shared Resource core facility, for acquiring the FIB-SEM datasets. We thank Alice Chuang (Richard Ruiz Department of Ophthalmology and Visual Science, McGovern Medical School) for statistical analysis.
Data availability
All the data used to create the figures in the manuscript have been provided as source data files for Figures 2, 3, 4, 5 and 8.The following data sets were generated.Ishibashi M, Keung J, Ribelayga CP, Massey SC (2018) Confocal imaging of the outer plexiform layer in mouse retina. Collection ID: 30675648bee2309e, URL: https://download.brainimagelibrary.org/30/67/30675648bee2309e/In the public domain at BIL http://www.brainimagelibrary.org/index.htmlSinger JH (2018) SBF-SEM of mouse retina. eel001. URL: https://wklink.org/9712In the public domain at webKnossos https://webknossos.org/Morgan CW, Aicher SA, Carroll JR (2019) FIB-SEM of the outer plexiform layer in light-adapted mouse retina. EM1 and EM2, URL: https://bossdb.org/project/ishibashi2021In the public domain at BossDB https://bossdb.org/
Article and author information
Author details
Funding
National Institute of Mental Health (RF1MH127343)
- Catherine W Morgans
- Sue A Aicher
- Christophe P Ribelayga
- Stephen C Massey
National Eye Institute (EY029408)
- Christophe P Ribelayga
- Stephen C Massey
National Eye Institute (EY017836)
- Joshua H Singer
National Institute of Neurological Disorders and Stroke (P30NS061800)
- Sue A Aicher
National Eye Institute (P30EY028102)
- Stephen C Massey
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Fred Rieke, University of Washington, United States
Ethics
Animal experimentation: All animal procedures were reviewed and approved by the Animal Welfare Committee at the University of Texas Health Science Center at Houston (AWC-20-0138) or by our collaborators' local Institutional Animal Care and Use Committees.
Version history
- Received: August 13, 2021
- Preprint posted: September 6, 2021 (view preprint)
- Accepted: April 25, 2022
- Accepted Manuscript published: April 26, 2022 (version 1)
- Accepted Manuscript updated: April 27, 2022 (version 2)
- Version of Record published: June 6, 2022 (version 3)
Copyright
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Metrics
-
- 1,984
- Page views
-
- 437
- Downloads
-
- 12
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Neuroscience
Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β and misfolded tau proteins causing synaptic dysfunction, and progressive neurodegeneration and cognitive decline. Altered neural oscillations have been consistently demonstrated in AD. However, the trajectories of abnormal neural oscillations in AD progression and their relationship to neurodegeneration and cognitive decline are unknown. Here, we deployed robust event-based sequencing models (EBMs) to investigate the trajectories of long-range and local neural synchrony across AD stages, estimated from resting-state magnetoencephalography. The increases in neural synchrony in the delta-theta band and the decreases in the alpha and beta bands showed progressive changes throughout the stages of the EBM. Decreases in alpha and beta band synchrony preceded both neurodegeneration and cognitive decline, indicating that frequency-specific neuronal synchrony abnormalities are early manifestations of AD pathophysiology. The long-range synchrony effects were greater than the local synchrony, indicating a greater sensitivity of connectivity metrics involving multiple regions of the brain. These results demonstrate the evolution of functional neuronal deficits along the sequence of AD progression.
-
- Medicine
- Neuroscience
In recent years, there has been debate about the effectiveness of treatments from different fields, such as neurostimulation, neurofeedback, brain training, and pharmacotherapy. This debate has been fuelled by contradictory and nuanced experimental findings. Notably, the effectiveness of a given treatment is commonly evaluated by comparing the effect of the active treatment versus the placebo on human health and/or behaviour. However, this approach neglects the individual’s subjective experience of the type of treatment she or he received in establishing treatment efficacy. Here, we show that individual differences in subjective treatment - the thought of receiving the active or placebo condition during an experiment - can explain variability in outcomes better than the actual treatment. We analysed four independent datasets (N = 387 participants), including clinical patients and healthy adults from different age groups who were exposed to different neurostimulation treatments (transcranial magnetic stimulation: Studies 1 and 2; transcranial direct current stimulation: Studies 3 and 4). Our findings show that the inclusion of subjective treatment can provide a better model fit either alone or in interaction with objective treatment (defined as the condition to which participants are assigned in the experiment). These results demonstrate the significant contribution of subjective experience in explaining the variability of clinical, cognitive, and behavioural outcomes. We advocate for existing and future studies in clinical and non-clinical research to start accounting for participants’ subjective beliefs and their interplay with objective treatment when assessing the efficacy of treatments. This approach will be crucial in providing a more accurate estimation of the treatment effect and its source, allowing the development of effective and reproducible interventions.